Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I was going to enter XOXO at $1.90.. But I found another play with ELOY.. I had been watching XOXO since last week.. Now it decided to make a little move up without me..
Good luck to you
Larry
Michael SKGV makes me want to puke when I see it..
JPAL was on todays list.. I saw it at $4 and the bid was .21 with 200 share volume.. I decided that I am doing pretty well with my other stocks so I would wait to see what happens post split..
I have to go pick up my son so I'll chat with you later..
Larry
Entering post split that is..
Two 5-1 stock splits that I will be looking at entering next week are NBRG and JPAL..
Larry
Have a good night Michael..eom
Hello.. ELOY doing well :) eom
Hello gang, I made $800 off of GNLB.. Could of made more, but oh well.. A win is a win..
I have just bought into ELOY.. I have watched it creep up all week from a low of .60.. But it was over 2.00 two weeks ago and look at the insider buying.. And it has risen without any pumping.. We'll see..
http://biz.yahoo.com/t/e/eloy.html
I'm off to play some basketball.. I'll check back in later...
Have a good day
Larry
FYI Regarding SOCC Buyout for $7.50 a share.. 300,000 float. Probably to late to get it at its last price of $5.10
Sterling Financial Corporation of Spokane, Washington, To Acquire Source Capital Corporation
SPOKANE, Wash., June 27 /PRNewswire/ -- Sterling Financial Corporation (Nasdaq: STSA - news) today announced the signing of a definitive agreement to acquire Source Capital Corporation (Nasdaq: SOCC - news). The merger will be structured as a tax-free reorganization within the meaning of Section 368 (a) of the Internal Revenue Code of 1986, as amended, and will be accounted for as a ``purchase.''
Under the terms of the agreement, each share of Source common stock will be converted into shares of Sterling common stock at an initial price of approximately $7.50 per share on the date of the definitive agreement. The initial price will float within a range based upon the trading prices of Sterling's common stock prior to the completion of the merger, with a maximum and minimum number of shares to be issued by Sterling in exchange for all outstanding shares of Source common stock.
Sterling Chairman and Chief Executive Officer, Harold B. Gilkey, commented, ``We are pleased to welcome the employees, customers and investors of Source Capital Corporation into our company. This agreement allows us the opportunity to strengthen Sterling's capital base and to add some additional high quality employees to our loan-servicing and lending group. This transaction affords us the ability to increase lending opportunities while also keeping capital here in the Pacific Northwest.''
The Boards of Directors of both companies have unanimously approved the merger, subject to the approval of Source's shareholders and other customary closing conditions. Source's Board of Directors has agreed to recommend to the Source shareholders that they approve the merger. Source and Sterling have agreed to pay termination fees in the amounts of $300,000 and $75,000, respectively, under certain circumstances. In addition, Source has granted to Sterling an option to purchase up to 19.9% of Source's common stock currently outstanding. Certain shareholders of Source have agreed to vote to approve the merger.
Source Capital President and Chief Executive Officer, D. Michael Jones said, ``We are thrilled to have the opportunity to partner with Sterling. We have been unable to execute our business plan the way we would have liked to due to market conditions and the lack of reasonable financing. This merger enhances value for our shareholders and increases the liquidity of their investment.''
Commenting further on the acquisition, Mr. Gilkey, stated, ``This transaction is a win-win for the shareholders of both companies. The access to capital and other resources gives Sterling the opportunity to continue its regional growth. Additionally, the transaction reflects Sterling's long-term strategy of concentrating on its core businesses, including our ability to diversify loan portfolio opportunities across the region. Sterling will continue loan servicing on the Source commercial real estate portfolios as well as the mature equipment-leasing portfolio still on the Source books. Sterling welcomes and looks forward to a long-term opportunity for achievement and success with the Source team. The transaction is expected to be accretive to earnings following the closing. Due to the nature of Source's loan portfolio, Sterling has discounted certain assets to their fair value.''
Sterling Financial Corporation of Spokane, Washington, is as unitary savings and loan holding company, which owns Sterling Savings Bank. Sterling Savings Bank is a Washington State-chartered, federally insured stock savings association, which opened in April 1983. Sterling Savings Bank, based in Spokane, Washington, has branches throughout Washington, Idaho, Oregon and western Montana. Through Sterling's wholly-owned subsidiaries Action Mortgage Company and INTERVEST Mortgage Investment Company, it operates loan production offices in Washington, Oregon, Idaho and western Montana. Sterling's subsidiary Harbor Financial Services provides non-bank investments, including mutual funds, variable annuities, and tax-deferred annuities, through regional representatives throughout Sterling Savings' branch network.
Source Capital Corporation is a commercial financial services Company specializing in commercial real estate lending. The Company is headquartered in Spokane, Washington and has two operating subsidiaries, Source Capital Leasing Company and Source Capital Finance, Inc., which are also located in Spokane, Washington.
Witherspoon, Kelley, Davenport & Toole, P.S. served as legal counsel to Sterling. Feldman Financial Advisors, Inc. acted as financial advisers and Paine Hamblen Coffin Brooke & Miller, LLP served as legal counsel to Source.
Source and its directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Source in connection with the Merger. Information about the directors and executive officers of Source and their ownership of Source common stock is set forth in Source's Annual Report on Form 10-KSB/A for the period ending December 31, 2000. Additional information regarding the interests of these participants may be obtained by reading the joint prospectus/proxy statement regarding this transaction when it becomes available.
Sterling Financial and Source Capital will host a teleconference regarding the transaction on Thursday, June 28, 2001 at 11 a.m. EDT. Investors, analysts and other interested parties may dial into the teleconference at 712-271-1152 and use the password ``STERLING.'' A replay will be available from approximately 1:00 p.m. EDT on June 28, 2001 until July 20, 2001 at 5:00 p.m. EDT. The replay number is 402-220-9121. Sterling's news releases may also be accessed on the Internet at www.sterlingsavingsbank.net. For additional information on Source Capital visit their web site at www.sourcecapital.com.
I hope that you are feeling better Patsy..eom
Take care Michael...eom
Thanks for the input..eom
Hey Michael keep saying as you see it! MOPP was a good pick.. And probably still is.. I'm sure that there are more people that are grateful to get your opinions then there are that just want to bash.. I think that you do a great job.. I appreciate your input.. In fact I need your opinion on CALY.. Moved up big this morning then news came out and it has risen a few cents... Any thoughts.. TIA
Larry
HCEN HealthCentral.com ---- 1-50 R/S 06/28/2001 ---- ----
New symbol (HCEND). Refer to Daily List of 6/25
GNLB Still Rebounding :).eom
RAZF Moving back up.. I might have got out to early.. But I am not complaining.. You have to take a profit when you can..
Larry
Hello Gang, I told you yesterday that I bought RAZF @ .54 sold all my 16,700 shares @.73 a few minutes ago.. I will look to re enter possibly.. :)
Larry
GNLB Could be a bounce play...
FDA Notifies Genelabs That Aslera(TM) NDA Is Not Approvable
June 26, 2001 23:17:00 (ET)
REDWOOD CITY, Calif., and CORONA, Calif., Jun 26, 2001 /PRNewswire via COMTEX/ -- Genelabs Technologies, Inc. (GNLB, Trade) and Watson Pharmaceuticals, Inc. (WPI, Trade) announced today that the U.S. Food and Drug Administration (FDA) has issued a "not approvable" letter with respect to Genelabs' New Drug Application (NDA) for Aslera(TM) (prasterone) for the treatment of women with mild to moderate systemic lupus erythematosus (SLE or lupus). The agency cited various issues in the letter, primarily relating to the interpretation of efficacy and safety data submitted in the NDA.
(Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/19990728/GNLBLOGO )
Genelabs is committed to working with the FDA to address the deficiencies cited and expects to meet with the FDA promptly to clarify the issues raised and the steps required to be taken before the NDA may be approved. The companies stated that they intend to continue the efforts toward approval of this product because both Genelabs and Watson believe in its potential to improve the lives of women suffering from the debilitating effects of lupus.
Aslera is being developed by Genelabs and is exclusively licensed to Watson in North America. Genelabs is seeking approval of Aslera as a first-line therapy for women with mild to moderate SLE to improve disease activity and symptoms, and also to reduce corticosteroid requirements.
Genelabs Technologies, Inc., is a biopharmaceutical company engaged in the discovery and development of a new class of pharmaceutical products that target DNA. By acting directly on the genetic material, Genelabs' technology can be applied to a wide range of therapeutic applications, including cancer; autoimmune disorders; and infectious diseases caused by fungi, bacteria, parasites and viruses. Apart from its research, Genelabs is developing Aslera(TM) for systemic lupus erythematosus under a license from Stanford University.
Watson Pharmaceuticals, Inc., headquartered in Corona, California, is a leading specialty pharmaceutical company that develops, manufactures, markets and distributes branded and generic pharmaceutical products. Watson pursues a growth strategy combining internal product development, strategic alliances and collaborations and synergistic acquisitions of products and businesses.
This press release contains certain statements of a forward-looking nature relating to future events or future business performance. Any such statements that refer to Genelabs' or Watson's estimated or anticipated future results, product development efforts or performance, the prospects and proposed timeframe for product approval or market launch, if approved, or other non-historical facts are forward-looking and reflect respectively Genelabs' and Watson's current perspective of existing trends and information. Genelabs and Watson each disclaim any intent or obligation to update these forward-looking statements. These forward-looking statements involve risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such statements. Such risks and uncertainties include, among others, the difficulty of predicting the timing or outcome of product development efforts and FDA or other regulatory agency approval or actions including prospects or timing of product approval or market launch, if ultimately approved, of Aslera(TM); market acceptance of products and the impact of competitive products and pricing; the availability on commercially reasonable terms of third party sourced products; dependence on sole source suppliers and risks associated with production interruptions or shipment delays at such suppliers; successful compliance with extensive, costly, complex and evolving governmental regulations and restrictions; exposure to product liability and other lawsuits and contingencies; and other risks and detailed in the relevant party's most recent filings with the Securities and Exchange Commission.
This and past press releases of Genelabs Technologies, Inc. are available at Genelabs' web site at www.genelabs.com and at PR Newswire's Company News on Call at www.prnewswire.com.
This and past press releases of Watson Pharmaceuticals, Inc. are available at Watson's web site at www.watsonpharm.com and at PR Newswire's Company News on Call at www.prnewswire.com.
CONTACT: press, James A. D. Smith, President, 650-562-1424, or investors, Matthew M. Loar, Vice President, Finance, 650-562-1424, both of Genelabs Technologies, Inc.; or press, Sara Swee, Director, Corp. Communications of Watson Pharmaceuticals, Inc., 909-270-1400, or Christopher Katis, or investors, Jim Byers, both of Morgen-Walke Associates, Inc., 415-296-7383, both for Watson Pharmaceuticals, Inc. MAKE YOUR OPINION COUNT - Click Here http://tbutton.prnewswire.com/prn/11690X32518184
SOURCE Genelabs Technologies, Inc. CONTACT: press, James A. D. Smith, President, 650-562-1424, or investors, Matthew M. Loar, Vice President, Finance, 650-562-1424, both of Genelabs Technologies, Inc.; or press, Sara Swee, Director, Corp. Communications of Watson Pharmaceuticals, Inc., 909-270-1400, or Christopher Katis, or investors, Jim Byers, both of Morgen-Walke Associates, Inc., 415-296-7383, both for Watson Pharmaceuticals, Inc. /Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/19990728/GNLBLOGO AP Archive: http://photoarchive.ap.org PRN Photo Desk, 888-776-6555 or 212-782-2840 URL: http://www.genelabs.com http://www.prnewswire.com
Copyright (C) 2001 PR Newswire. All rights reserved.
Thanks for the info! Hopefully it willl be good news...
Larry
Good morning Michael and all, I was watching CALY run premarket.. I don't know why it has gotten all the buying pressure this morning..
Larry
Someone mentioned PEPM the other day..
There was 1 trade today.. 60,000 shares @ $.80 = $48,000
Here is a link to their PR on May 15... Possible merger and 4-1 forward split...http://biz.yahoo.com/prnews/010518/cgf014.html
Larry
Have a good night everyone... eom
Patsy, I hope that you will be back to full strength by this weekend.. I'm glad to hear that you are taking antibiotics. Very incredible what a little tick can do to the human body..
Good luck to you..
Larry
RAZF Volume going crazy.. I hope that it pops...
I don't know why, but NAWL has risen slowly over the past few months...
Larry
I agree. I think that he has enough followers to help give it a little bit more help...
Larry
Good to see BMII move up for you.. I was worried for you on this one... Seems to be a lot of attention on this stock..
Larry
Hi Michael, Pennybuster is pushing CMKI now.. Saw his post on the STIPS board (RB)...
I got out of GTMH around $1.50.. Stayed in to long.. Oh well, next split please..LOL
Hopefully Patsy will be back to good health soon!
Larry
Hello Gang, Bottom fishing with RAZF @ .54.. I made some quick cash on MCLD, EXDS, and MFNX over the past few trading days..
COVDE is moving up also..
Larry
Have a good night everyone.. I'm off to another Doctors appt. with my new one..
Take care
Larry
Good luck to you Michael(ammo).. Be careful.. I hope all goes well and will be looking forward to seeing you back on the boards :)
Larry
Hi ammo, I would be careful with DFCU also, but I would have taken a chance on it if I would have been around and seen that post..
Larry
I think that it has to be just MMM with GTMH... Who would be sitting around waiting on the bid to raise a nickle so that they can unload? No one.. IMHO
Larry
Michael, I figured DFCU was a P&D.. Just wished I had known about it..LOL
This was the first time that I have received my split shares on the very day that it split... I have been in smaller splits that I have had the shares credited to my account quickly, but not on such a large ratio as this..
Larry
GTMH getting a little bit more action.. I remember ESYG went to $2.50 and then fell down to $.60 within a few days.. A week later (if that) it was trading over $3.00...
Larry
Hi Flanker, now that you said that about GTMH a buy goes through at $2.25.. Still waiting to see what unfolds..
Larry
DFCU 100,000 float up 300% today.. I had never heard of this one before.. I wish that I had ealier with only 100k in the float..
Still holding GTMH and waiting..
Larry
GTMH Bid 2.25 - Ask 2.30
Haeding back up! Kind of scary earlier.. I logged in to see 1.65 x 1.75.. I still hold all of my shares..
Well I'm back to work.. Take care
Larry
RDVN Float 122,875...
The aggregate market value of the 122,875 shares of common stock of the registrant held by non-affiliates on December 31, 2000, was approximately $45,078.00
At December 31, 2000, a total of 320,000 shares of common stock were outstanding
RDVN info
Name and Address of Common Stock Owned Percent of Common
of Beneficial Owner Beneficially Stock Outstanding
-------------------------- ------------------ ------------------
*Randy J. Sasaki ....................... 512,500 (1) 38.8%
90 Madison Street, Suite 707
Denver, Colorado 80206
*John D. Brasher Jr. ................... 525,000 (1) 39.7%
90 Madison Street, Suite 707
Denver, Colorado 80206
*Thomas Liston .......................... -0- -0-
2604 South Xanadu Way
Aurora, Colorado 80014
*All directors and executive
executive officers (3 persons) .... 1,037,500 78.5%
(1) Includes 500,000 shares subject to purchase upon the exercise of options granted under the 1997 Compensatory Stock Option Plan.
The percentages reflected in the above table were calculated as if all the 1,000,000 stock options had been exercised. The current officers and directors of Renegade may be deemed to be "promoters" or "founders" of Renegade
http://www.pinksheets.com/quote/filings.jsp?url=%2Fredirect.asp%3Ffilename%3D0001050502%252D01%252D0...
http://www.edgarpro.com/edgar_conv_html%5C2001%5C05%5C14%5C0001000096-01-500124.html#FIS_TOP_OF_DOCU...
PLAN of OPERATION
Renegade is a blank check company whose plan of operation over the next twelve months is to seek and, if possible, acquire an operating business or valuable assets by entering into a business combination.. Renegade will not be restricted in its search for business combination candidates to any particular geographical area, industry or industry segment, and may enter into a combination with a private business engaged in any line of business, including service, finance, mining, manufacturing, real estate, oil and gas, distribution, transportation, medical, communications, high technology, biotechnology or any other. Management's discretion is, as a practical matter, unlimited in the selection of a combination candidate. Management of Renegade will seek combination candidates in the United States and other countries, as available time and resources permit, through existing associations and by word of mouth. This plan of operation has been adopted in order to attempt to create value for Renegade's shareholders.
Thanks for the warning Franc...
I just think that any buying pressure would drive this one up because the O/S is very low.. I think that the float would have to be extremely low. And from the volume chart graph that I posted ealier you can see that since Oct. 2000 the price has gone up with little volume during that time.. I wouldn't plan on staying in long term... Just thought that it would make a good short squeeze play.. The company doesn't have any money, yet the stock has risen instead of fallen..
It kind of acts like the MM's are short all ready and if we all started bidding on this at once then it might pop.. I also like the fact that the price is low and the spread is tight..
I don't know if it would work.. Just an idea.. Thanks again..
Larry
Skeena, I'm interested in cornering the float on some of these shell plays... So if others are they'll have to let us both know :) I just like the number of O/s shares in RDVN and the spread is tight.. Also the volume has been very low...
Have a good night
Larry